Sigachi Industries Q1 Results: Net profit rebounds to ₹8.14 crore
Sigachi Industries returned to profitability in Q1FY26 with a consolidated net profit of ₹8.14 crore, reversing a ₹100.97 crore loss from the prior year. Revenue dipped slightly to ₹121.27 crore. The board forfeited ₹22.87 crore worth of lapsed convertible warrants and proposed re-appointments for two independent directors.

*this image is generated using AI for illustrative purposes only.
Sigachi Industries Limited ( sigachi industries ) reported a consolidated net profit of ₹8.14 crore for the quarter ended June 30, 2026, marking a sharp turnaround from the ₹100.97 crore loss recorded in the corresponding period of FY25. The company’s standalone net profit also recovered to ₹6.50 crore, compared to a ₹99.14 crore loss in Q1FY25.
Consolidated revenue from operations stood at ₹121.27 crore, down slightly from ₹128.25 crore in Q1FY25. Standalone revenue was ₹98.28 crore, lower than the ₹110.98 crore reported in the prior year quarter. The previous year’s results were significantly impacted by exceptional losses of ₹121.01 crore, whereas no such exceptional items were reported in the current quarter.
Financial Performance
The company’s profitability improved across both standalone and consolidated metrics. Consolidated profit before tax reached ₹10.09 crore, up from a loss of ₹100.99 crore in Q1FY25. Standalone profit before tax was ₹7.79 crore, compared to a loss of ₹99.20 crore in the same period last year.
| Metric | Consolidated Q1FY26 (₹ cr) | Consolidated Q1FY25 (₹ cr) | Standalone Q1FY26 (₹ cr) | Standalone Q1FY25 (₹ cr) |
|---|---|---|---|---|
| Revenue from Operations | 121.27 | 128.25 | 98.28 | 110.98 |
| Profit Before Tax | 10.09 | (100.99) | 7.79 | (99.20) |
| Net Profit/Loss | 8.14 | (100.97) | 6.50 | (99.14) |
| EPS (Basic) | ₹0.18 | (₹2.63) | ₹0.17 | (₹2.59) |
Segmental Insights
The pharmaceuticals segment remained the primary revenue driver. Consolidated revenue from pharmaceuticals was ₹108.21 crore, while the operational and management segment contributed ₹13.06 crore. In standalone figures, pharmaceuticals revenue stood at ₹85.22 crore.
Corporate Actions
The Board of Directors, meeting on August 13, 2026, approved the lapse and forfeiture of convertible warrants issued under SEBI ICDR Regulations 2018. A total of 3.51 crore warrants lapsed as holders failed to exercise conversion options within the 18-month tenure. Consequently, an amount of ₹22.87 crore stands forfeited. The warrants were originally allotted on August 10, 2023, at an issue price of ₹26.1 per warrant.
Additionally, the board recommended the re-appointment of Ms. Dhanalakshmi Guntaka and Mr. Janardhana Reddy Yeddula as independent directors for five-year terms, subject to shareholder approval at the ensuing annual general meeting. Mr. Chidambarnathan, retiring by rotation, also offered himself for re-appointment.
What the Numbers Show
The current quarter’s profitability is entirely operational, devoid of the massive exceptional losses that dragged down FY25 results. While revenue declined modestly year-on-year, the absence of exceptional items allowed the company to return to positive net earnings, highlighting a stabilization in core operations despite softer top-line growth.
Historical Stock Returns for Sigachi Industries
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -3.41% | +4.69% | +11.75% | +18.00% | -14.09% | -55.97% |
Will Sigachi Industries be able to sustain its operational profitability in Q2FY26 given the year-on-year decline in revenue from operations?
How might the forfeiture of ₹22.87 crore from lapsed convertible warrants impact the company's capital structure and future fundraising strategies?
What specific operational improvements or cost-cutting measures contributed to the turnaround from a ₹100.97 crore loss to a profit, excluding the one-time exceptional items?


































